A randomized phase III study assessing SVV-001 in combination with Opdivo and Yervoy compared to Opdivo and Yervoy alone in TEM8 positive neuroendocrine tumors and neuroendocrine carcinomas
Latest Information Update: 14 Apr 2021
At a glance
- Drugs SVV-001-Seneca Therapeutics (Primary) ; Ipilimumab; Nivolumab
- Indications Neuroendocrine carcinoma; Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Seneca Therapeutics
- 14 Apr 2021 New trial record
- 12 Apr 2021 According to a Seneca Therapeutics media release, this study will begin later in 2021.